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Background: High flow nasal cannula therapy (HFNC) may increase aerosol generation, putting 43 
healthcare workers at risk, including from SARS-CoV-2.  44 
 45 
Aim: This study examined whether use of HFNC increases near-field aerosols and if there is a 46 
relationship with flow rate.  47 
 48 
Methods: Subjects aged four weeks to 24 months were recruited. Each child received HFNC 49 
therapy at different flow rates. Three stations with particle counters were deployed to measure 50 
particle concentrations and dispersion in the room: station one within 0.5 m, station two at 2 m, 51 
and station three on the other side of the room. We measured carbon dioxide (CO2) and relative 52 
humidity. Far-field measurements were used to adjust the near-field measurements.  53 
 54 
Findings: We enrolled ten children ranging from 6-23 months (median 9 months). Elevated CO2 55 
indicated the near-field measurements were in the breathing plane. Near-field breathing plane 56 
concentrations of aerosols with diameter 0.3 – 10 µm are elevated by the presence of the patient 57 
with no HFNC flow, relative to the room far-field, by 0.45 #/cm
3
. While we observed variability 58 
between subjects in their emission and dispersion of particles, we did not find an association 59 
between HFNC use, at any flowrate, and near-field particle counts.  60 
 61 
Conclusion: This method of particle sampling is feasible in hospital settings; correcting the near-62 
patient aerosol and CO2 levels for the room far-field may provide proxies of exposure risk to 63 
pathogens generated. In this pilot, near-patient levels of particles with a diameter between 0.3-10 64 
µm and CO2 were not affected by the use of HFNC.  65 
 66 
 67 










High flow nasal cannula therapy (HFNC) provides respiratory support for children across 70 
a range diagnoses including asthma, pneumonia and bronchiolitis. World Health Organization 71 
(WHO) guidance suggests that HFNC does not cause wide-spread dispersion of droplets from 72 
patients.
1
 However, empirical data in clinical settings is lacking on whether HFNC contributes to 73 
aerosol dispersion. While children typically have more mild and even asymptomatic infections 74 
with SARS-CoV-2, respiratory disease and co-infection with other viruses have been reported.
2
 75 
HFNC has been treated as an aerosol generating procedure (AGP) in the United States given 76 
concern around particle generation, typically characterized in the health care field as droplet 77 
(≥5µm) and droplet nuclei (<5 µm).
3
 Due to the increased concern for SARS-CoV-2 78 
transmission with use of AGPs, many hospitals require the use of N-95 masks, gowns, and other 79 
personal protective equipment when patients are receiving HFNC. Determining the risk of 80 
aerosol generation from HFNC has important implications for resource management and 81 
infection control measures. 82 
 SARS-CoV-2 transmission may occur due to aerosols and large droplets, with some 83 
evidence of more widespread dispersion than typical with large droplets.
4
 Most studies to date 84 
have investigated transport of large droplets from patients undergoing HFNC. Kotoda et al.
5
 used 85 
a mannequin model to examine the effect of high flow nasal cannula at 60 L/min and observed 86 
large droplets (>50 µm) transported 30 cm, but not 5 m from the mannequin’s face. A report 87 
examining adults coughing with and without the application of high flow nasal cannula (60 88 
L/min) showed no significant difference in the distance of “visible” food-dye containing 89 
droplets;
6









as those >100 µm. These studies indicate large droplets are not effectively transported over long 91 
distances due to the forced air exiting the patient’s nasal and oral cavity.  92 
Studies have also employed smoke as a tracer to evaluate impacts of HFNC on room air 93 
flows and as proxies of exhaled air exposure. Hui et al.
7
 used intrapulmonary smoke in a 94 
mannequin model to evaluate dispersion of exhaled air, as measured by the extent of light-95 
scattering as a function of distance from the patient. They showed an increase in “exhaled air 96 
dispersion” from 65 mm with HFNC flow of 10 L/min to 172 mm with HFNC flow of 60 L/min. 97 
Using smoke particles as tracers and an adult human head with a lung model attached, Elshof et 98 
al.
8
 examined the dispersion of 100 µm droplets using HFNC with a lung simulator. They 99 
described an estimated dispersion range of 100 µm droplets of between 18.8 and 33.4 cm from 100 
the individual using flow rates between 30-60 L/min. They also noted that HFNC increased the 101 
distance of exhaled smoke to nearly one metre under several conditions whereas a non-rebreather 102 
or Venturi mask did not influence the distance beyond normal breathing.
8
  103 
This pilot study sought to examine whether HFNC therapy use in children generates 104 
elevated particle levels in the near-field of the patient’s breathing plane. We measured 105 
concentrations of particles and carbon dioxide in hospital rooms with varying HFNC flow rates. 106 
Our study addresses several knowledge gaps concerning HFNC and particle generation and 107 
dispersion as it: i) addresses an unstudied population, children, ii) was conducted in a clinical 108 
care facility with human subjects, and iii) directly measured aerosols with diameter 0.3 - 10 µm 109 
and carbon dioxide in the near-field breathing plane and room far-field. The goals were to 110 
examine the feasibility and precision of the sampling procedure to characterize AGP in field 111 
settings, to generate data to inform the safe use of this therapy, and to inform resource 112 










Subject eligibility and recruitment:  115 
Subjects were recruited through fliers and email announcements. Inclusion criteria were 116 
children at a gestation-corrected age 4 weeks to 24 months and otherwise healthy. Subjects 117 
already hospitalized receiving HFNC for a respiratory illness had to have a negative SARS-CoV-118 
2 test. We screened potential subjects for the exclusion criteria of SARS-CoV-2 exposure or 119 
symptoms, prematurity (<37 weeks) and chronic cardiac or pulmonary conditions. This study 120 
was approved as human research through the institutional IRB, and all parents provided written 121 
consent.  122 
Experimental procedure: 123 
 Hospital rooms were chosen from available paediatric acute care rooms (patient room, 124 





, respectively and volumes of 77 m
3
 and 55 m
3
, respectively. CO2 tracer 126 
decay tests conducted in patient and procedure rooms resulted in an air change rate of 8.4 and 127 
11.0 h
-1
, respectively (Figure S1 of Supporting Information), in general agreement with 128 
ASHRAE design recommendations for total air changes through the space.  Tracer decay test 129 
analysis shown in Figure S1 uses the room steady-state CO2 concentration prior to the injection 130 
of CO2 as the CO2 level entering the space from the supply air. The fraction of outdoor vs. 131 
recirculated air is unknown, though we note guidelines are 2 and 3 outdoor air changes per hour, 132 
respectively, for patient and procedure rooms.
9
 Air entering the rooms is treated with MERV10 133 
and MERV15 filtration. Figure 1 shows the configuration of the supply and return register in the 134 
patient rooms, where most experiments took place. In patient rooms, the supply and return 135 









2.5 m apart. For the two patients with respiratory illness who were part of the study 137 
measurements were made in a negative pressure room, with an additional negative flow duct on 138 
the wall abutting the floor, approximately 3 m from the patient.  We did not observe cycling of 139 
the HVAC system in patient or procedure rooms during measurements. 140 
Subjects were placed on a hospital bed with a parent in the room, with the parent wearing 141 
a cloth or surgical mask at all times. A high-flow nasal cannula system (Fisher and Paykel’s 142 
Optiflow Junior, circuit RT 330) with an appropriately sized nasal cannula for each subject’s size 143 
and weight was set-up by a qualified respiratory therapist.  144 
Ambient air in the hospital room was first sampled with the door closed and no patient 145 
present (background condition) for 15 minutes. The child was then connected to the HFNC, flow 146 
was then increased from 0 to 0.5 L/kg/min, to 1 L/kg/min then finally to 2 L/kg/min, then back to 147 
0 L/kg/min and repeated the cycle one more time for a total of two measurements per subject at 148 
each flow rate. Each cycle lasted about seven minutes. An experimental timeline is shown in 149 
Figure 1. HFNC air was heated to approximately 37°C and humidified. No supplementary 150 
oxygen was provided. We conducted a positive control following the completion of the protocol 151 
twice over the course of the study. In this control, particle and CO2 levels were measured in the 152 
breathing plane ~0.5 m from the nasal/oral cavity of member of the research team during and 153 
after volitional coughing.  154 
We recruited ten children ranging from 6-23 months (median nine months) and their 155 
parents to participate in the study between September and November 2020. The median weight 156 
of participants was 9.8 kg (range 7.3-14.0 kg). The flow rates were calculated for each child at 157 
0.5 L/kg/min, 1 L/kg/min and 2 L/kg/min with a max flow rate in this study of 25 L/min, which 158 








environmental conditions during measurements. Two patients (P02 and P03) are excluded from 160 
subsequent analysis as measurements occurred during periods of extremely elevated outdoor air 161 
pollution due to wildfires in the region. For patients with respiratory illness (P08 and P10), we 162 
were not able to vary the HFNC flowrate and have no background measurements.  163 
Particle and carbon dioxide measurement:  164 
Three sampling stations were deployed in the room of each study participant prior to their 165 
arrival, excepting P08 and P10 who were present prior to sampling. The main sampling location 166 
(station 1, Figure 1) was set within the patient’s breathing plane at a distance of ~0.5 m. This 167 
main sampling station was set up similar to O’Neil et. al
10
. An optical particle sizer (TSI/OPS 168 
3330) and scanning mobility particle sizer (TSI/NanoScan SMPS 3910) counted particles 169 
ranging from 0.01 to 10 μm at a time resolution of one-minute. A condensation particle counter 170 
(TSI, P-Trak 8525) measured particles ranging 0.02 to 1 μm in one second time interval. 171 
Isokinetic sampling (constant flow rate into the sampling outlet) was not possible due to the 172 
variability in airflows in the room and due to the exhalations of the patient. A CO2 analyzer 173 
(LICOR LI-820) measured CO2 levels in one second intervals. A temperature and relative 174 
humidity sensor (Onset, S-THB-M002) measured in one-minute interval.  175 
Two additional sampling stations (station 2 and 3, Figure 1) were installed to monitor the 176 
room. Each station included a particle counter (Purple Air, PA-II-SD), measuring particle 177 
number concentration in six size bins from 0.3 - 10 μm and recording every 80 seconds, and a 178 
CO2 sensor (Onset, MX1102) recording every minute. In this study, we normalize the data 179 
reported by station 1 (near-field) to that of station 3 (far-field), which we take as the ambient, 180 
mixed room particle and CO2 level. Note that we lacked particle number concentrations <0.3 μm 181 









diameter, this investigation subsequently focuses on particulate matter with aerodynamic 183 
diameter 0.3 – 10 μm (PM0.3-10), the range most likely to explain small particle transmission of 184 
SARS-CoV-2 . 185 
Field co-location of instruments: 186 
The particle counters and CO2 sensors in stations 1 and 3 were co-located during the 187 
background period, when the room was unoccupied for 15 min. We used these periods to 188 
develop correction factors that were applied to the far-field (station 3) sensor during periods of 189 
participant occupancy. The OPS size bins were averaged to match the six bins of the PA. A 190 
correction factor for each size bin was calculated as in equation 1: 191 
  ( )  
     ( )̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅
    ( )̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅
 
eq. 1 
where   ( ) is the correction factor for size bin x,      ( )̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅ is the time-averaged OPS value in 192 
size bin x, and     ( )̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ̅̅  is the time-averaged PA value in size bin x. We used a linear regression 193 
to correct the values given by the far-field CO2 sensor (Onset MX1102) to that of the LICOR LI-194 
820 during the 15-minute background period.   195 
Calculations of  PM and  CO2: 196 
 To account for the changing concentration of PM0.3-10 and CO2 in the room due to 197 
processes other than the patient undergoing HFNC, we normalize the near-field (station 1) 198 
measurements to that of the far-field (station 3). We report the normalized metrics as  PM0.3-10 199 
(#/cm
3
) and  CO2 (ppm) calculated as shown in equations 2 and 3: 200 
   ( ) =       ( )-      ( ) eq. 2 








where       ( )is the time-varying particle concentration at station 1 (#/cm
3
),      ( )is the 201 
corrected (i.e., eq. 1) particle concentration at station 3,         ( )is CO2 concentration at 202 
station 1 (ppm), and        ( )is the corrected CO2 concentration at station 3 (ppm). 203 
Statistical testing: 204 
We evaluate statistical significance of differences in means of  PM0.3-10 and in medians 205 
of  CO2 across HFNC flow rates using a student t-test for  PM0.3-10 and a Wilcoxon rank sum 206 
test for  CO2. Tests for normality and statistical testing employed the average of each HFNC 207 
condition conducted in duplicate across the six healthy subjects (i.e., 12 independent samples of 208 
 PM0.3-10 and  CO2 for each condition). 209 
Results:  210 
 Measurements of particle concentrations, CO2, temperature and relative humidity (RH) 211 
for two example patients are shown in Figure 2. In the top panel, room particle concentrations 212 
are reported in the near-field breathing plane (station 1) and far-field (station 3) of the room, with 213 
the second panel showing the difference ( PM0.3-10). For patient 01, near-field is generally higher 214 
than far-field, resulting in positive  PM0.3-10. We also observed sharp spikes in  CO2. This 215 
implies measurements captured patient exhalations, as the source of CO2 in the room is the 216 
patient. Conversely, in Patient 06 there are lower levels of particles in the near-field vs. far-field, 217 
resulting in a generally negative  PM0.3-10. This is possibly due to a low particle generation rate 218 
for this patient, room mixing conditions, and/or other sources of particles during this experiment 219 
(e.g., changes in the room airflows due to HVAC operation or movement by the parent around 220 
the room). For positive controls we observe elevated particle and CO2 concentrations following 221 
the volitional cough, shown at elapsed time ~100 min for both patients. A child’s parent, present 222 








However, instruments were installed with inlet targeting the breathing plane of the child only. 224 
This possible confounder is present consistently across each subject’s varied HFNC conditions, 225 
as the parent was present with the child for the duration of the test.  226 
Distributions of  PM and  CO2 are shown in Figure 3 across baseline conditions (HFNC 227 
at 0 L/kg/min), HFNC with flow, and positive control. Similar plots are shown for size-resolved 228 
particles in Figure S2 of the Supporting Information. Shown in Figure 3 are the measurements of 229 
particles and CO2 made with 1-min time resolution. Across all six patients, we observe that the 230 
presence of the patient alone (i.e., baseline) results in an increase in the near-field PM (i.e., 231 
median  PM0.3-10 is positive). Presence of HFNC flow does not significantly change the mean 232 
 PM0.3-10 compared to the baseline condition (see p-values in Table S2). Measurements of  CO2 233 
made for the six patients shown in Figure 3 indicate that median  CO2 is consistently positive. 234 
This implies that near-field measurements generally occurred in the exhalations of the patient. 235 
Again, no significant change is observed with HFNC flow compared to the baseline condition 236 
(see p-values in Table S2). The volitional cough positive control resulted in substantially higher 237 
 PM0.3-10 and  CO2.  238 
 While median  PM0.3-10 and  CO2 are consistently positive, there existed across-subject 239 
variability in  PM0.3-10 and  CO2. For example, Patients 01, 05, 07, and 09 had consistently 240 
positive  PM0.3-10 while Patients 04 and 06 were consistently negative (Figure 4a). Values of 241 
 CO2 were more consistently positive than  PM0.3-10, as shown in Figure 4b, though again, there 242 
exists variability across subjects.  243 
In Figure 5, we show the results of  PM0.3-10 and  CO2 for the two patients recruited who 244 
had respiratory illness; results are limited to only one flowrate as we did not alter the patients’ 245 









from healthy patient studies conducted on the same respective days. As in healthy patients, we 247 
observe variability in median  PM0.3-10, with P08 negative and P10 positive. In contrast,  CO2 248 
for both patients is greater than zero, implying measurements occurred in patient breathing 249 
planes.   250 
Discussion: 251 
Results of this pilot study indicate, across patients, that HFNC does not appear to be 252 
substantial source of aerosol generation or dispersion in the near-field beyond that of the 253 
patient’s presence. Human breath contains particles - while results are variable across time for 254 
each patient and between patients, the median  PM0.3-10 reported in this measurement is roughly 255 
consistent with the previous measurements of particle number concentrations in human breath. 256 
Johnson et al.
11
 report particle levels in speaking and coughing emissions in the size range of 0.5 257 
- 1000 µm of 0.16 #/cm
3
 and 0.22 #/cm
3
, respectively. In our study, the complex fluid mechanics 258 
occurring in the patient’s breathing plane due to exhaled breath, HFNC airflow, and the room 259 
airflows complicate further theoretical calculations of particle concentrations or emission rate 260 
originating from the patient. Humans also generate particles from activity.
12
 Particles originating 261 
from the respiratory system versus patient movement, for example, cannot be differentiated here.   262 
Median values of  PM0.3-10 decreased slightly, though not statistically significantly, with 263 
increasing HFNC flow rate. We speculate this may be the result of enhanced mixing between 264 
forced air from subject and room air with higher velocities at higher HFNC flow conditions. 265 
There are no statistically significant differences across  PM0.3-10 or  CO2 for any comparison of 266 
flow conditions. We set the threshold of significance as p < 0.0083 for 95% confidence with 267 
Bonferonni correction for multiple comparisons. Calculated p-values are shown in the Table S2 268 








Results shown in Figure 4 reveal high variability in near-patient concentrations of PM 270 
and CO2. The explanation for the mechanism behind these observations is beyond the scope of 271 
this paper, though we speculate it is possible that patients with negative  PM0.3-10 may be low 272 
emitters of particles or positioned in the space such that enhanced particle deposition is occurring 273 
in the turbulence generated from airflows interacting with the patient and associated equipment 274 
(bedding, instruments, etc.). Particles also deposit in the respiratory system.
13
 Patient 06 and 275 
Patient 04 measurements were conducted during relatively high room background PM levels, 276 
perhaps contributing to the negative  PM0.3-10 observed. We note that prior studies have 277 
observed large variability in particle emission rate and concentrations in exhalations of humans 278 
during breathing and speaking.
14–18
 There is debate on the size of particles that are considered 279 
infectious, with droplet nuclei playing a larger role than previously considered
19
 – one strength 280 
of our study is that we were able to measure a broad range of potentially infectious particles, 281 
including droplet nuclei. 282 
Differences in near-field to far-field CO2 were larger and more pronounced than for PM. 283 
CO2 levels in human breath are ~100x higher than ambient levels (~38,000 vs. 400 ppm).
20
 In 284 
contrast, particle concentrations in human breath in the size range 0.3 - 10 µm are expected to be 285 
similar or lower than background levels measured in patient rooms.
14
 There also exists large 286 
variation in particle generation rates during breathing and coughing, with the presence of a 287 
respiratory infection causing increased particle generation rate.
21
  288 
In contrast to the variability in  PM0.3-10 shown,  CO2 is variable but more consistently 289 
positive (Figure 4b), implying that measurements were generally made in the breathing planes of 290 
the patients. There does not appear to be a relationship between elevated  CO2 and  PM0.3-10 , 291 









had the highest  CO2 for three of four HFNC flow conditions, but  PM0.3-10 was consistently 293 
near the median value reported. Again, we speculate that this is a result of differences in particle 294 
generation across subjects that are not related to metabolism (e.g., unknown physiological factors 295 
that have been previously suggested as explaining “superemission” of aerosol during speech
15
).  296 
Our limited sample of two patients with respiratory illness shown in Figure 5 297 
demonstrates variability in near-field elevations of particles, with Patient 10 showing greater 298 
 PM0.3-10 than all healthy patients by a substantial margin. This appears largely driven by a 299 
difference in the behavior of particles 0.3 – 0.5 µm, as this size range dominated the particle 300 
number concentration. For both patients with respiratory infection we note there was an elevation 301 
in  PM0.5-1, a size range that a prior study shows is significantly elevated during a respiratory 302 
infection.
22
 We did not have the ability to vary HFNC flowrate for these subjects, and so lack a 303 
baseline period of no HFNC flow for comparison.   304 
HFNC is also widely used in adult patients. We suspect adults could have greater 305 
dispersion as typical volumes used (60 L/min) are much higher, even scaled for tidal volume, 306 
though strongly suggest the experiment should be completed.  307 
Conclusions: 308 
 In this pilot study, our measurements indicate near-field (~0.5 m) breathing plane 309 
concentrations of aerosol and carbon dioxide are elevated by the presence of the patient with no 310 
HFNC flow. Addition of HFNC flow in the range of 0.5 - 2 L/kg/min did not significantly 311 
change the magnitude of near-field PM or CO2, corrected for the room far-field. These findings 312 
indicate that HFNC use in children may not substantially elevate clinician aerosol exposures 313 
greater than the presence of the patient alone, though we observe variability across patients that 314 









thus proof of clinical insignificance is not possible with the present dataset. Future studies can 316 
use these pilot data to inform experimental design to ensure sufficient power in comparing 317 
measurements of CO2 and aerosols in a field setting that are subject to substantial variability. For 318 
example, a sample size of ~165 patients would be necessary to achieve power = 0.9 in comparing 319 
average  PM0.3-10 across baseline and 0.5 L/kg/min HFNC conditions. In addition to larger scale 320 
studies, future studies should evaluate potential aerosol generating procedures in controlled 321 
settings where particle emission rates can be calculated; these data would enable dispersion 322 
modeling of particles emitted by patients. It is also worth noting that measurements of aerosols 323 
and CO2 serve as proxies for exposure to a pathogen of concern. Relating measurements of CO2 324 
and aerosols to likelihood of disease transmission is out of the scope of this pilot study. Such 325 
efforts should consider the known large variability in emission rates of viruses across humans for 326 
activities like breathing and speech.
23
 Further study of the impacts of HFNC on particle 327 
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Figure captions 403 
 404 
Figure 1. Panel A) Layout of patient room and sampling locations with stars R and S 405 
respectively corresponding to the return and supply registers on the ceiling, and Panel B) 406 
Timeline of experiments for each patient 407 
 408 









Figure 2. Example particle and CO2 concentrations in the breathing plane of two patients. 410 
Shading annotations shows the condition of the experimental protocol. Note the difference in 411 
scales for PM and ΔPM across the two subjects. 412 
 413 









Figure 3. Panel A) Distributions of measured  PM0.3-10 and Panel B)  CO2 for six patients 415 





percentiles, and whisker designates upper and lower extent of outliers in the distribution. Note 417 
that   indicates reported measurements are the difference between the near-field breathing plane 418 
and the coincident ambient room concentration (far-field), as explained in the text. 419 
 420 









Figure 4. Panel A) Across-subjects variability in  PM0.3-10 and Panel B)  CO2. Each bar is the 422 
median across 1-min averaged measurements at each HFNC flow condition for the indicated 423 
subject. The error bars show the range across the 1-min averaged measurements (max-min). The 424 
upper error bar for P01 at 0.5 L/kg/min extends to 310 ppm, not shown for figure clarity. 425 
 426 









Figure 5. Size resolved  PM0.3-10 and  CO2 for two patients with diagnosed respiratory illness. 428 
Patient 08 was 3 months old and HFNC flowrate of 3 LPM, Patient 10 was 24 months with 429 
HFNC flowrate of 15 LPM. Bars show median values of 1-min averaged measurements while 430 
error bars show the range across a 10-min monitoring period.  431 
 432 
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